These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 21978390)

  • 21. The soluble mannose receptor is released from the liver in cirrhotic patients, but is not associated with bacterial translocation.
    Laursen TL; Rødgaard-Hansen S; Møller HJ; Mortensen C; Karlsen S; Nielsen DT; Frevert S; Clemmesen JO; Møller S; Jensen JS; Bendtsen F; Grønbaek H
    Liver Int; 2017 Apr; 37(4):569-575. PubMed ID: 27706896
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fasting hyperglucagonemia in patients with transjugular intrahepatic portosystemic shunts (TIPS).
    Raddatz D; Rossbach C; Buchwald A; Scholz KH; Ramadori G; Nolte W
    Exp Clin Endocrinol Diabetes; 2005 May; 113(5):268-74. PubMed ID: 15926112
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes of transjugular intrahepatic portosystemic shunt creation for flow-enabled dissolution of spleno-mesenterico-portal venous thrombosis.
    Lakhoo J; Gaba RC
    Diagn Interv Imaging; 2016 Nov; 97(11):1085-1093. PubMed ID: 27481577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of transjugular intrahepatic portosystemic shunt (TIPS) on blood volume distribution in patients with cirrhosis.
    Busk TM; Bendtsen F; Henriksen JH; Fuglsang S; Clemmesen JO; Larsen FS; Møller S
    Dig Liver Dis; 2017 Dec; 49(12):1353-1359. PubMed ID: 28729141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
    Testino G; Ferro C; Sumberaz A; Messa P; Morelli N; Guadagni B; Ardizzone G; Valente U
    Hepatogastroenterology; 2003; 50(54):1753-5. PubMed ID: 14696397
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension.
    Colombato L
    J Clin Gastroenterol; 2007; 41 Suppl 3():S344-51. PubMed ID: 17975487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Transjugular intrahepatic portosystemic shunt and combination with percutaneous transhepatic or transsplenic approach for the treatment of portal vein thrombosis with or without cavernomatous transformation].
    Han GH; Meng XJ; Yin ZX; Wang JH; He CY; Liang J; Guo XG; Liu J; Ding L; Wu KC; Fan DM
    Zhonghua Yi Xue Za Zhi; 2009 Jun; 89(22):1549-52. PubMed ID: 19953883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Short- and long-term hemodynamic effects of transjugular intrahepatic portosystemic shunts: a Doppler/manometric correlative study.
    Lafortune M; Martinet JP; Denys A; Patriquin H; Dauzat M; Dufresne MP; Colombato L; Pomier-Layrargues G
    AJR Am J Roentgenol; 1995 Apr; 164(4):997-1002. PubMed ID: 7726065
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Measuring the effect of a study meal on portal concentrations of glucagon-like peptide 1 (GLP-1) in non diabetic and diabetic patients with liver cirrhosis: transjugular intrahepatic portosystemic stent shunt (TIPSS) as a new method for metabolic measurements.
    Raddatz D; Nolte W; Rossbach C; Leonhardt U; Buchwald A; Scholz KH; Ramadori G
    Exp Clin Endocrinol Diabetes; 2008 Aug; 116(8):461-7. PubMed ID: 18770489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Shunting branch of portal vein and stent position predict survival after transjugular intrahepatic portosystemic shunt.
    Bai M; He CY; Qi XS; Yin ZX; Wang JH; Guo WG; Niu J; Xia JL; Zhang ZL; Larson AC; Wu KC; Fan DM; Han GH
    World J Gastroenterol; 2014 Jan; 20(3):774-85. PubMed ID: 24574750
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of transjugular intrahepatic portosystemic shunt on glycometabolism in cirrhosis patients.
    Su AP; Cao SS; Le Tian B; Da Zhang Z; Hu WM; Zhang Y; Wang ZL; Babu SR; Hu T
    Clin Res Hepatol Gastroenterol; 2012 Feb; 36(1):53-9. PubMed ID: 22099870
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time-Harmonic Elastography of the Liver is Sensitive to Intrahepatic Pressure Gradient and Liver Decompression after Transjugular Intrahepatic Portosystemic Shunt (TIPS) Implantation.
    Tzschätzsch H; Sack I; Marticorena Garcia SR; Ipek-Ugay S; Braun J; Hamm B; Althoff CE
    Ultrasound Med Biol; 2017 Mar; 43(3):595-600. PubMed ID: 27979668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of transjugular intrahepatic portosystemic stent shunt on systemic cardiocirculatory parameters.
    Saugel B; Mair S; Meidert AS; Phillip V; Messer M; Nennstiel S; Berger H; Gaa J; Wagner JY; Schneider H; Schmid RM; Huber W
    J Crit Care; 2014 Dec; 29(6):1001-5. PubMed ID: 25220530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk factors for overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt creation in patients with liver cirrhosis.
    Tong H; Gan C; Wei B; Wang ZD; Li XD; Qian SJ; Huan H; Zhang LH; Yang Z; Chen YL; Gu YH; Chen LX; Yang YH; Wu H; Tang CW
    J Dig Dis; 2021 Jan; 22(1):31-40. PubMed ID: 33128287
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement.
    Albillos A; de la Hera A; González M; Moya JL; Calleja JL; Monserrat J; Ruiz-del-Arbol L; Alvarez-Mon M
    Hepatology; 2003 Jan; 37(1):208-17. PubMed ID: 12500206
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemokine (C-X-C motif) ligand 11 levels predict survival in cirrhotic patients with transjugular intrahepatic portosystemic shunt.
    Berres ML; Lehmann J; Jansen C; Görtzen J; Meyer C; Thomas D; Zimmermann HW; Kroy D; Schumacher F; Strassburg CP; Sauerbruch T; Trautwein C; Wasmuth HE; Trebicka J
    Liver Int; 2016 Mar; 36(3):386-94. PubMed ID: 26212075
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between pre-TIPS liver perfusion by the portal vein and the incidence of post-TIPS chronic hepatic encephalopathy.
    Hassoun Z; Deschênes M; Lafortune M; Dufresne MP; Perreault P; Lepanto L; Gianfelice D; Bui B; Pomier-Layrargues G
    Am J Gastroenterol; 2001 Apr; 96(4):1205-9. PubMed ID: 11316171
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Follow-up study of 116 cases of transjugular intrahepatic portosystemic shunt in the treatment of cirrhotic portal hypertension].
    Liu MH; Zhou F; Wang XB; Chen LP; Li GZ; Zhao Q
    Zhonghua Gan Zang Bing Za Zhi; 2018 Aug; 26(8):596-600. PubMed ID: 30317791
    [No Abstract]   [Full Text] [Related]  

  • 39. Transjugular intrahepatic portosystemic shunt creation with the Viatorr expanded polytetrafluoroethylene-covered stent-graft.
    Hausegger KA; Karnel F; Georgieva B; Tauss J; Portugaller H; Deutschmann H; Berghold A
    J Vasc Interv Radiol; 2004 Mar; 15(3):239-48. PubMed ID: 15028808
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic value of conventional ultrasound and shear wave elastography in detecting transjugular intrahepatic portosystemic shunt dysfunction.
    Han H; Yang J; Jin WK; Li X; Zhang F; Zhuge YZ; Wu M; Yang B
    Acta Radiol; 2021 Dec; 62(12):1575-1582. PubMed ID: 33251812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.